As of November 7, 2026, Hemab Therapeutics Holdings, Inc. is a publicly traded company (Nasdaq: COAG). The largest holder reporting an active stake on Schedule 13D is AI Den-mab LLC (an Access Industries fund, per the filing), at 10.4%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D, May 11, 2026).
Is this your company?
About to sign with, pay or invest in Hemab Therapeutics Holdings, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Hemab Therapeutics Holdings, Inc. a real, registered company?
- Hemab Therapeutics Holdings, Inc. files with the SEC under CIK 2114044 (its SEC filings).
- Its shares are listed under the ticker COAG on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Cambridge, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under HEMAB THERAPEUTICS HOLDINGS INC in our court records and SEC 8-K records (as of 2026-11-07).
- Leadership changes: the latest reported is Keli Walbert, Director (Form 8-K filed 2026-09-24). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-06).
Who are Hemab Therapeutics Holdings, Inc.'s owners and officers?
Hemab Therapeutics Holdings, Inc.: incorporated in Delaware; business address in Cambridge, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-06).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | Fmr LLC | 10.4% |
| Schedule 13G, 2026-08-14 | Novo Holdings A/S | 9% |
| Schedule 13G, 2026-08-14 | Behzad Aghazadeh | 7.06% |
| Schedule 13G, 2026-08-12 | Capital International Investors | 7.7% |
| Schedule 13G, 2026-08-07 | Raymond Debbane | 5.1% |
| Schedule 13G, 2026-08-06 | Fmr LLC | 7.9% |
| Schedule 13G, 2026-08-05 | Sofinnova Crossover Ii Slp | 5.4% |
| Schedule 13G, 2026-05-11 | Ra Capital Management, L.P. | 16.6% |
| Schedule 13D, 2026-05-11 | Ai Den-Mab LLC | 10.4% |
| Schedule 13G, 2026-05-08 | Deep Track Capital, LP | 8.15% |
Questions about who owns Hemab Therapeutics Holdings, Inc.
Who owns Hemab Therapeutics Holdings, Inc.?
On this page, 9 holders' latest ownership filings report 5% or more of Hemab Therapeutics Holdings, Inc.: Ra Capital Management, L.P. (16.6%, Schedule 13G, filed 2026-05-11), Fmr LLC (10.4%, Schedule 13G/A, filed 2026-11-06), Ai Den-Mab LLC (10.4%, Schedule 13D, filed 2026-05-11), Novo Holdings A/S (9%, Schedule 13G, filed 2026-08-14) and Deep Track Capital, LP (8.15%, Schedule 13G, filed 2026-05-08); 4 more are listed above.
Who are the largest shareholders of Hemab Therapeutics Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Hemab Therapeutics Holdings, Inc. on this page are Ra Capital Management, L.P. (16.6%), Fmr LLC (10.4%) and Ai Den-Mab LLC (10.4%).
When did Ra Capital Management, L.P. buy into Hemab Therapeutics Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G, filed 2026-05-11, reporting 16.6%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Hemab Therapeutics Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Hemab Therapeutics Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Hemab Therapeutics Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
20 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-24 | Keli Walbert | Director | appointed | |
| Form 8-K, 2026-09-24 | Keli Walbert | appointed | ||
| Form 8-K, 2026-05-11 | Laura Tadvalkar | Director | departed |
Which insiders own Hemab Therapeutics Holdings, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- RA Capital, a 10% owner: 6,444,637 shares (13.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-17).
- RA Capital Healthcare Fund LP, a 10% owner: 6,444,637 shares (13.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-17).
- , a 10% owner: 6,444,637 shares (13.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-17).
- , a 10% owner: 6,444,637 shares (13.8% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-06-17).
- RA Capital Nexus Fund II, L.P., a director: 6,314,525 shares (13.5% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-05-06).
Shares outstanding: 46,712,117 as of 2026-07-31, from the company's latest SEC cover page.
How much has Hemab Therapeutics Holdings, Inc. raised?
Latest IPO step: Hemab Therapeutics Holdings, Inc. filed its final IPO prospectus, ticker COAG (424B4, 2026-05-01).
IPO filings: 424B4, 2026-05-01, S-1/A, 2026-04-30, S-1/A, 2026-04-28, S-1/A, 2026-04-27, S-1, 2026-04-10; ticker COAG on Nasdaq Global Select Market.
Keep reading
More on Hemab Therapeutics Holdings, Inc. and the records around it.
Hemab Therapeutics Holdings, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026), MAPLIGHT THERAPEUTICS, INC. (Jul 2026)
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Arrowhead Pharmaceuticals, Inc. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Scribe Therapeutics, Inc. (Jul 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Related pages
Leadership changes5%+ holdersIPO filings
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/hemab-therapeutics